Effect of a daily dose of Lactobacillus brevis CD2 lozenges in high caries risk schoolchildren by Guglielmo Campus et al.
ORIGINAL ARTICLE
Effect of a daily dose of Lactobacillus brevis CD2 lozenges
in high caries risk schoolchildren
Guglielmo Campus & Fabio Cocco & Giovanna Carta &
Maria Grazia Cagetti & Charlotte Simark-Mattson &
Laura Strohmenger & Peter Lingström
Received: 29 January 2013 /Accepted: 8 April 2013 /Published online: 5 May 2013
# The Author(s) 2013. This article is published with open access at Springerlink.com
Results At t0, the plaque-pH and ms concentration values
were similar in both groups. Mean areas (AUC5.7 and
AUC6.2) were significantly greater in the control group at t1,
t2 and t3. L. brevis CD2 lozenges significantly reduced sali-
vary ms concentrations and bleeding. The subjects from the
test group showed a statistically significant decrease (p=0.01)
in salivary ms concentration. At t2, a statistically significantly
lower bleeding value was recorded in the test group compared
with the control group (p=0.02).
Conclusions Six weeks’ use of lozenges containing L. brevis
CD2 had a beneficial effect on some important variables
related to oral health, including a reduction in plaque
acidogenicity, salivary ms and bleeding on probing. (Trial
Registration Number NCT01601145 08/21/2012)
Keywords Probiotic . Lactobacillus brevisCD2 . Caries .
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Introduction
Dental caries is the interaction over time between cario-
genic microflora, a diet rich in fermentable carbohydrates
and host factors, including saliva secretion rate and buff-
ering capacity [1]. Caries is still one of the most com-
mon diseases among children, although a declining
prevalence trend has been recorded in western countries
[2–7]. Preventive programmes to control caries risk fac-
tors, focusing on dietary modification and enhancing host
resistance through the use of fluoride and sealants, are
recommended [8]. However, in recent years, a complete
eradication of caries-associated micro-organisms has
proved to be difficult and almost impossible but quite
unwise [9].
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Abstract
Objectives A double-blind, randomised, placebo-controlled
clinical trial was performed to validate the hypothesis that the
use of lozenges containing Lactobacillus brevis CD2
(Inersan®, CD Investments srl) may reduce plaque pH, salivary
mutans streptococci (ms) and bleeding on probing, during a 6-
week period, in a sample of high caries risk schoolchildren.
Methods A total of 191 children (aged 6–8 years), presenting
two to three carious lesions and a salivary ms concentration of
≥105 CFU/ml, were enrolled and divided into two groups, an
L. brevisCD2 lozenge group and a no L. brevis lozenge group,
and examined at baseline (t0), after 3 weeks (t1), after 6 weeks
of lozenge use (t2) and 2 weeks after the cessation of lozenge
use (t3). Plaque pH was assessed using the microtouch tech-
nique following a sucrose challenge. The area under the curve
(AUC5.7 and AUC6.2) was recorded. Salivary ms were count-
ed, and bleeding on probing was assessed.
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Recent studies have shed a new light on the potential for
using probiotics for the prevention of oral diseases, i.e. a shift
in the microbial population towards a pathogen-associated
population, which is central to the development of the major
oral diseases (caries and periodontal disease). Preliminary data
on probiotics obtained by various research groups [10, 11]
have been encouraging, but further randomised clinical stud-
ies are still required clearly to establish their potential for
preventing and treating oral infections. These studies will
enable the identification of the probiotics that are best suited
for oral use, as well as the vehicles that are the most appro-
priate for administration: food products (cheese, milk, yogurt)
or supplements (chewing gum, lozenges).
The main goal for the use of probiotics in caries preven-
tion is the inhibition of the proliferation of cariogenic bac-
teria (mainly Streptococcus mutans) and the reduction of
their adherence to the tooth surfaces. In vitro studies [12, 13]
have demonstrated the capacity of probiotics to inhibit
Streptococcus sobrinus. The inhibition of S. mutans growth
and biofilm formation by several probiotic strains like
Lactobacillus plantarum DSM 9843, Lactobacillus reuteri
PTA 5289, L. reuteri ATCC 55730 and so on has been
reported [11, 14, 15]. A significant decrease in salivary S.
mutans concentration was observed following the consump-
tion of probiotic ice cream containing Bifidobacterium lactis
Bb-12 or chewing gum containing L. reuteri [10, 11].
The hypothesis of this study is that the use of lozenges
containing Lactobacillus brevis CD2 may reduce plaque pH,
salivary mutans streptococci (ms) concentration and bleed-
ing on probing in a sample of high caries risk
schoolchildren. To validate this hypothesis, a randomised
clinical trial was designed and performed.
Materials and methods
Study design and registration of the study
The study was designed as a randomised clinical trial,
approved by the Ethics Committee at the University of
Sassari, Italy (no. 108SS/2012), and registered at
www.clinicaltrials.gov (NCT NCT01601145). The study
was carried out in Sassari, where the total number of chil-
dren aged 6–8 years in 2011 was 3,258. Power analysis was
performed using G*Power 3.1.3 for Apple using ANOVA
for repeated measures and, taking account of a disease
prevalence of 0.51 with an effect size of 0.06 and an error
probability of 0.05, the number of subjects in each group
was set at 78, with an actual power of 0.95. The sample size
was calculated on the basis of previous studies of caries
prevalence [3, 4]. It was increased by 15 % to safeguard the
estimates at an optimal level of precision (5 %) against the
possible effect of disease reduction compared with previous
studies and the number of non-responders. The total theo-
retical sample size was set at 180.
Preliminary screening
Screeningwas carried out fromNovember 2011 to January 2012
to select children who presented two to three manifest carious
lesions in the permanent and/or primary dentition and a salivary
mutans streptococci (ms) concentration of ≥105 CFU/mL.
Carious lesions were diagnosed when there was a cavity at
dentinal level (D3). Subjects with a history of systemic antibiotic,
topical fluoride (except for toothpaste) or chlorhexidine treat-
ment within 30 days before baseline were excluded.
Schoolchildren were recruited using systematic cluster
sampling; each class was identified as a cluster and com-
piled into a list. The first cluster was randomly chosen,
while the others were selected at the systematic interval of
three classes. In all, 564 children were recruited for the
preliminary screening.
An information leaflet, explaining the aim of the study
and requesting their child’s participation with signed con-
sent, was given to parents or guardians. Only children with
parents’ signed consent were called for examination (534
subjects). The clinical examination and the saliva sampling
were performed during the school day; 526 children showed
up at the time scheduled for the examination, 208 met the
inclusion criteria and were enrolled in the study. The flow
chart of the study design is shown in Fig. 1.
A second leaflet explaining the aim of the clinical trial
and requiring the child’s participation was mailed to all
parents/guardians of the 208 children. The investigation
had a randomised, placebo-controlled study design, includ-
ing a plaque acidogenicity evaluation, a microbiological
evaluation and bleeding on probing, with an experimental
period of 8 weeks.
The clinical trial was carried out from January to July
2012. The study design included a first examination (saliva
sample, plaque-pH evaluation and periodontal probing) at
baseline (t0), a second after 3 weeks (t1), a third after 6 weeks
(t2) of lozenge use and a final examination 2 weeks after the
end of lozenge use (t3; Fig. 1). One week before the start of
the experiment, all the subjects began to use a 1,400-μg/g
AmF toothpaste (Gaba-Colgate, Rome), for daily oral hy-
giene. A soft toothbrush was likewise provided, and they
were asked to avoid any other oral hygiene adjuvant.
Moreover, the children received a patient diary, which
informed them that the use of any fluoride-containing oral
hygiene products (other than the toothpaste handed to the
participants), any fluoride-containing mineral water or black
tea, fish meals and commercial probiotic products was not
allowed during the study.
Two groups of children were created: (1) a test group,
using non-sucrose lozenges containing L. brevis CD2, and
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(2) a control group, using non-sucrose lozenges with no
active ingredient. Randomisation was carried out on an
individual basis by GC and FC using Excel® 2010 for
Mac. Ten subjects were absent at the start of the experiment,
so the final study sample was 198. At the t1 interim evalu-
ation, five children were excluded as they did not return the
empty lozenge bottle (three from the test group and two
from the control group), at t2 more children were excluded,
three from the test group and five from the control group
(four children had received systemic antibiotics therapy and
four did not return the empty lozenge bottle), and, at t3, four
children refused to complete the experiment (two from the
test group and two from the control group). As a result, 181
children concluded the 8-week experimental period: 91 in
the test group and 90 in the control group.
Treatment and sample collection
The L. brevis CD2 lozenges (Inersan®, CD Investments srl,
Rome, Italy) contain 2,000,000,000 colonies of L. brevis
CD2, sweeteners (mannitol, aspartame, fructose), anti-
caking agents (talc, silicon dioxide, magnesium stearate)
and banana flavouring. The lozenges for the control group
contained exactly the same ingredients, except for the L.
brevis CD2. The two lozenges were identical in weight
(1 g), form, colour and packing. They were produced and
supplied by CD Investments Srl (Rome, Italy) and coded as
either “green” or “red”. The code was sealed by an inde-
pendent monitor and was not broken until the statistical
analysis was finalised. Each subject took two lozenges a
day, one in the morning and one in the evening, for the
whole experimental period.
The parents/guardians were asked to make no changes to the
dietary and oral hygiene habits of their children. Toothbrushing
was not allowed for at least 1 h after the use of the lozenges.
In order to evaluate the administration of the products at
school and home, teachers and parents were given lozenges
necessary for 2 weeks at a time and were asked to return the
empty bottles when receiving those necessary for the fol-
lowing period. This procedure was repeated throughout the
whole experimental period. The compliance and any ob-
served side effects of the administration of the products
Fig. 1 Flow chart of the study design
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were assessed by means of a questionnaire administered to
the participants’ parents at t2.
Plaque-pH evaluation
The children refrained from eating/drinking 1 h before plaque-
pH evaluation. No toothbrushing or other tooth-cleaning
methods were allowed on the morning of the measurement
day. Plaque acidogenicity was assessed using the microtouch
technique after a sucrose challenge. Evaluations of pH were
carried out at two proximal sites (between the deciduous
molars) on the left and right sides of the upper jaw. The pH
of each site was measured in triplicate at six different time
points: before the sucrose rinse and 2, 5, 10, 15 and 20 min
after a 1-min rinse with 10 ml of 10 % sucrose, using active
movements. An iridium touch microelectrode, diameter
0.1 mm (Beetrode NMPH-1, World Precision Instruments,
Sarasota, FL, USA) [16], with a porous glass reference elec-
trode, was used (MERE 1, WPI, Sarasota, FL, USA). Before
each session of pH evaluation, the electrode was calibrated
using buffer solution at pH 7.00 and 4.00 [17].
Microbiological analyses
Non-stimulated whole saliva was collected for 150 s in sterile
vials (Nunc, Kamstrup, Denmark). The samples were processed
within 45 min of collection at the Department of Microbiology
(University of Sassari). The samples were serially diluted in
sterile PBS (Sigma Chemicals, St. Louis, MO, USA). Aliquots
of 5 μl were inoculated onMitis-SalivariusBacitracin Agar [18]
for the evaluation ofms. The plates were incubated in a 5%CO2
environment at 37 °C for 72 h, and the colony forming units
(CFU) were identified by morphology, size and colour and
counted in a stereomicroscope; the ms concentration in saliva
was expressed as log10 CFU per milliliter.
Bleeding on probing
Bleeding on probing was recorded dichotomously as bleed-
ing or not, 30 s after the gentle manipulation of the tissue at
the depth of the gingival sulcus by a probe. Bleeding on
probing was checked at t0, t2 and t3 by one calibrated
examiner (GC) before the plaque-pH evaluation. Intra-
examiner reliability was assessed before the start of the
study on 20 subjects. Cohen’s kappa value for the bleeding
score was 0.81. Examinations were carried out under
standardised conditions, using optimal artificial lighting, a
plain mirror and a WHO-CPI probe.
Statistical methods
The mean pH of the pH readings for each individual site was
calculated. The mean for the two sites at the different time
points was calculated, as well as minimum pH and maxi-
mum pH fall. The area between reference pH (AUC5.7 and
AUC6.2) and the pH curve was calculated using “Plaque-
pH” software [19]. The salivary ms concentrations were
transformed to log10 values to normalise the data, and the
mean and standard error (SE) was calculated for each group
and time point. Data were analysed for statistically signifi-
cant differences using repeated one-way and two-way mea-
sures analysis of variance (ANOVA). At t2, the subjects
were divided according to salivary ms concentration (<105
and ≥105), and the areas under the plaque-pH curve (AUC5.7
and AUC6.2) for the two groups were compared in order to
evaluate the possible relationship between salivary ms con-
centration and plaque pH. The difference between t0 and t2
in the AUC and in the salivary concentration of ms was also
calculated for each subject, and a linear regression analysis
was computed.
The number of bleeding sites was added together, and
the result was expressed as a percentage of the total
number of surfaces. Adjustment of type I error due to
multiple testing is not considered necessary due to the a
priori ordering of the hypotheses. Hypothesis testing has
to be stopped if a null hypothesis cannot be rejected at the
5 % error level α. This procedure maintains a constant
global level of α=5 %. All the analyses were carried out
using Stata SE software 10.0. A p value of <0.05 was
considered statistically significant.
Results
No adverse effects were reported by the children in either
group. A total of 181 children completed the experimental
period (Fig. 1): 91 subjects in the test group and 90 in the
control group. There were 16 drop-out subjects (8.1 %)
during the 2-month period. The mean number of D3
lesions in all dentition (deciduous/permanent) was 2.61
in the test group and 2.54 in the control group (p=0.36).
At t0, plaque pH and the salivary ms concentration were
similar in both groups, with no statistically significant
differences for the two variables observed (p=0.18 and
p=0.48, respectively).
Table 1 shows the mean±SE for AUC5.7 and AUC6.2
during the trial. At baseline, the values for AUC5.7 and
AUC6.2 were similar in the two groups (p=0.60 and p=
0.15, respectively). Mean areas (AUC5.7 and AUC6.2) were
statistically significantly different at the following time
points (t1, t2 and t3), with the largest difference at t2. The
differences were statistically dissimilar in each group when
it came to time intervals (p<0.01 in the L. brevis CD2 group
and 0.03 in the control group for AUC6.2). The minimum
pH showed small variations among the four time points for
the test group, whereas in the control group, a decrease was
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detected between t0 and t2; p values were statistically sig-
nificant at the t1 and t2 inter-group comparison. The inter-
group comparison of the maximum pH fall was statistically
significant at t1, t2 and t3, p=0.01, p<0.01 and p=0.04,
respectively (data not shown).
Similar results were noted for the salivary ms con-
centration (Table 2). The children from the test group
showed a statistically significant decrease (p=0.01) in
the salivary ms concentration (5.4 at t0, 4.9 at t2). In
children from the control group, the salivary ms con-
centration remained at the same level during the whole
experimental period. Areas under the curve at t2
(Table 3) were statistically significantly smaller in chil-
dren from the test group (p=0.01 AUC5.7 and p=0.03
AUC6.2) in relation to the salivary ms concentration, if
compared with the control group, for children at both
ms concentrations (>105, ≤105).
The bleeding score at t0 was similar in the two groups
(32.8 % in the control group and 33.4 % in the test
group), while, at t2, a statistically significantly lower
value was recorded in the test group compared with the
control group (p=0.02). At t3, the difference in bleeding
score was still statistically significant (p=0.03), with a
value of 24.4 [95 % confidence interval (CI)=19.0–30.1]
in the test group and 28.6 (95 % CI, 23.5–33.8) in the
control group (Fig. 2).
Discussion
The effect of L. brevis CD2, administered daily through loz-
enges at a frequency of two times/day, on plaque
acidogenicity, ms concentration and gingival bleeding in a
group of high caries risk children was evaluated. The main
finding from this randomised clinical trial is that L. brevis
CD2 lozenges were effective in reducing plaque acidogenicity
and salivary ms concentrations. A reduction in the bleeding
score was also observed in the test group. It has been docu-
mented that probiotics can act locally in the oral cavity
through the biofilm and systemically by modifying the im-
mune response [20].
A significant reduction in plaque acidogenicity was found
after 6 weeks’ use of the probiotic lozenges. The short-term
consumption (2 weeks) of probiotic lactobacilli has not been
found to influence plaque acidogenicity or ms levels in plaque
[15]. One interesting observation was that the effect on plaque
acidogenicity appeared to be reduced during the last 2 weeks
of the experimental period, when no product was used. This
indicates the importance of the continuous administration of
probiotic products in order to achieve a lasting effect on
different oral variables, as has previously been suggested
[12]. Probiotic bacteria can survive and grow in the oral
environment, although permanent colonisation is unlikely in
an established oral biofilm [21, 22].
Table 2 Concentration of
mutans streptococci (log10 CFU/
ml saliva: mean±SE) at t0, t1, t2
and t3 in the two groups of chil-
dren using lozenges with L.
brevis CD2 (test group) and loz-
enges without probiotic bacteria
(control group)
Time Test group Control group p value(one-way ANOVA)
t0 (baseline) 5.4±0.3 5.4±0.2 0.36
t1 (after 3 weeks’ lozenge use) 5.2±0.5 5.4±0.0 0.04
t2 (after 6 weeks’ lozenge use) 4.9±0.1 5.4±0.4 0.01
t3 (2 weeks after the end of lozenge use) 5.1±0.4 5.4±0.4 0.02
p value (one-way ANOVA) 0.01 0.48
Table 1 AUC5.7 and AUC6.2 (mean±SE) during the experimental period in the two groups of children using lozenges with L. brevis CD2 (test
group) and lozenges without probiotic bacteria (control group)
Time AUC5.7 (pH×min) AUC6.2 (pH×min)
Test group Control group p value
(one-way ANOVA)
Test group Control group p value
(one-way ANOVA)
t0 (baseline) 11.3±0.5 11.1±0.4 0.60 22.0±0.8 21.1±0.7 0.15
t1 (after 3 weeks’ lozenge use) 9.1±0.3 11.8±0.6 0.02 17.6±0.8 20.8±0.4 0.03
t2 (after 6 weeks’ lozenge use) 7.2±0.4 11.2±0.7 <0.01 14.7±0.2 20.9±0.8 <0.01
t3 (2 weeks after the end of
lozenge use)
10.4±0.2 12.0±0.2 0.03 20.4±0.8 21.2±0.5 0.12
p value (one-way ANOVA) <0.01 0.14 <0.01 0.03
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Previous studies have suggested that the intake of various
strains of the lactobacilli species may reduce the counts of
salivary mutans streptococci in children, even if it is only for
the observational period [10, 23, 24]. In the present study, a
statistically significant reduction in the salivary ms counts
was observed. One of the explanatory hypotheses is linked
to the release of arginine deiminase by the probiotic in
general [25] and by L. brevis CD2 in particular [26].
Arginine deiminase is an enzyme that is normally confined
to the prokaryotic kingdom [27]. This enzyme is able to
catalyse the conversion of arginine to citrulline and ammo-
nia; as many bacteria can use arginine as their only source of
energy for growth, an arginine deficiency can reduce bacte-
rial proliferation [28].
The change in the concentration of ms in saliva may reflect
a change in the plaque microflora as well. Otherwise, some
other results would require more investigation. For instance,
the very low maximum pH at t1 for the test group is not
logical, and the same also holds true for the time of 10–
20 min for t3 and the test group; this is the reason why the
AUC increases. These are the reasons why the "minimum pH"
and "maximum pH fall" are not 100 % logical, when compar-
ing the test and control groups. One hypothesis could be that
people in the test group respond differently to the L. brevis
CD2. A high variability in the response to the effect of
different probiotics has been described and, in a recent review,
it was concluded that the same strain does not appear to be
ideal for everyone [20].
A significant reduction in gingival bleeding was found
after 6 weeks’ use of the probiotic lozenges and 2 weeks after
the cessation of use. The anti-inflammatory effects of L. brevis
CD2 administered through lozenges in a group of patients
with chronic periodontitis were studied [29]. One possible
explanation for the beneficial anti-inflammatory effects of L.
brevis CD2 could be its capacity to prevent the production of
nitric oxide and, consequently, the release of PGE2 and the
activation of MMPs induced by the nitric oxide.
To the authors’ knowledge, this study is the first
randomised clinical trial of the efficacy of probiotics in
relation to plaque acidogenicity. Furthermore, no previous
clinical trials have used the L. brevis CD2 as probiotic
strain. The findings are novel and fairly interesting, as the
lozenge administration was well accepted by the children
and the treatment proved to be effective and simple. In spite
of these positive aspects, it is important to underline that
these results were obtained in a, relatively speaking, short-
term period, and they had to be probably considered as
temporary benefits. Further investigations are needed to
evaluate a long-term effect on caries-related variables as
well as the caries incidence which was not the outcome of
this study. It is from the literature [30] well known that a
long-term administration of probiotic is needed to gain
health benefits. A strength of the present study is that also
gingival health was monitored, which is an important fea-
ture of children oral health.
In conclusion, the 6-week administration of probiotic
bacteria (L. brevis CD2) through lozenges is able to reduce
same important variables related to oral health. A reduction
of plaque pH, salivary mutans streptococci concentration
and bleeding on probing in a sample of high caries risk
schoolchildren can concur to reduce caries risk and to in-
crease gingival health. This study provides evidence in























Fig. 2 Bleeding score (percentage) recorded at t0, t2 and t3 in the two
groups of children using lozenge with L. brevis CD2 respective loz-
enge without probiotic bacteria (control). One-way ANOVA
Table 3 Areas under the curve (AUC5.7 and AUC6.2) in relation to salivary ms concentration (≤105 and >105) at t2 for the two groups of children
using lozenges with L. brevis CD2 (test group) and lozenges without probiotic bacteria (control group)
AUC5.7 AUC6.2
ms≤105 ms>105 p-value ms≤105 ms>105 p value
mean±SD (n) mean±SD (n) (one-way ANOVA) mean±SD (n) mean±SD (n) (one-way ANOVA)
Test group 4.3±0.7 (39) 6.2±0.9 (52) 0.01 8.1±0.4 (39) 9.3±0.4 (52) 0.03
Control group 8.0±0.2 (13) 9.1±0.8 (77) 0.12 13.3±0.4 (13) 14.8±0.2 (77) 0.04
p value (one-way ANOVA) <0.01 0.01 <0.01 <0.01
Mean±SE (N)
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